ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
5.75
-0.08 (-1.37%)
At close: Apr 28, 2026, 4:00 PM EDT
5.64
-0.11 (-1.91%)
After-hours: Apr 28, 2026, 5:37 PM EDT
Company Description
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Kristin Yarema |
Contact Details
Address: 12526 High Bluff Drive, Suite 345 San Diego, California 92130 United States | |
| Phone | 858 345 6265 |
| Website | inmagenebio.com |
Stock Details
| Ticker Symbol | IMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G207 |
| ISIN Number | US45175G2075 |
| Employer ID | 81-1697316 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristin Yarema Ph.D. | Chief Executive Officer, Director and Interim Principal Financial Officer |
| Bob Lally | Senior Vice President of Finance and Operations and Principal Accounting Officer |
| Dr. Kurinji Pandiyan Ph.D. | Chief Strategy and Operations Officer |
| Renuka Sivendran Ph.D. | Chief Technical Officer |
| Dr. Benjamin Porter-Brown M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | SCHEDULE 13G | Filing |
| Apr 21, 2026 | SCHEDULE 13D | Filing |
| Apr 13, 2026 | 424B3 | Prospectus |
| Apr 13, 2026 | 8-K | Current Report |
| Apr 3, 2026 | EFFECT | Notice of Effectiveness |
| Apr 2, 2026 | POS AM | Post-Effective amendments for registration statement |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 10, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |